CASE FILE CF-CLO-2025
非兴奋剂
SPECIMEN IDENTIFICATION
盐酸可乐定
作用機制
α-2肾上腺素能受体激动剂。刺激脑内突触前α-2受体,减少交感神经传出和 去甲肾上腺素 去甲肾上腺素 一种参与注意力、警觉性和战斗或逃跑反应的神经递质。许多ADHD药物会增加去甲肾上腺素的活性。 释放。在 ADHD 注意缺陷多动障碍 注意缺陷多动障碍 - 一种以注意力不集中、多动和冲动为特征的神经发育障碍。 中,被认为可改善前额叶皮层功能,减少多动,改善冲动控制。
化學結構
藥物標識符 (RxNorm)
RxNorm Ingredient
clonidine
RxCUI: 2599
別名
clonidine hydrochloride chemical Kapvay brand Nexiclon brand Catapres brand Clorpres brand Duraclon brand Onyda brand Javadin brand clonidine generic
品牌名映射
Kapvay
Nexiclon
Catapres
Clorpres
Duraclon
Onyda
Javadin
數據來源:
NLM RxNorm
各地區批准情況
Region Agency Year Ages Status
🇺🇸 US FDA 2010 6-17岁 Available
🇨🇳 CN NMPA — — Not Available
🇪🇺 EU EMA — — Not Available
🇯🇵 JP PMDA — — Not Available
🇬🇧 UK MHRA — — Not Available
副作用
COMMON
- 嗜睡/困倦 30-40%
- 疲劳 20-30%
- 头痛 15-20%
- 口干 10-20%
- 头晕 10-15%
- 易怒 10%
- 上呼吸道感染 10%
SERIOUS
- 低血压 可能出现明显血压下降
- 心动过缓 可能显著减慢心率
- 反跳性高血压 突然停药时严重;必须逐渐减量
- 镇静 可能很严重,尤其是治疗初期
- 房室传导阻滞 罕见的心脏传导异常
Seek medical attention immediately
顯示原始 YAML 數據 ARCHIVE +
FILE: clonidine.yaml Last updated: 2025-12-05
id: clonidine
brandNames:
US:
- Kapvay
- Catapres
CN: []
EU:
- Catapres
JP: []
UK:
- Catapres
AU:
- Catapres
CA:
- Catapres
genericName:
en: clonidine hydrochloride
zh: 盐酸可乐定
ja: クロニジン塩酸塩
manufacturers:
- name: Concordia Pharmaceuticals
region: US
product: Kapvay
- name: Boehringer Ingelheim
region: US
product: Catapres
chemicalStructure:
smiles: ClC1=CC=CC(Cl)=C1NC1=NCCN1
pubchemCid: 2803
molecularFormula: C9H9Cl2N3
imageUrl: https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/2803/PNG
wikipediaUrl: https://en.wikipedia.org/wiki/File:Clonidine.svg
drugClass: non-stimulant
drugClassLabel:
en: Non-Stimulant
zh: 非兴奋剂
ja: 非中枢刺激薬
category: alpha-2 adrenergic agonist
categoryLabel:
en: Alpha-2 Adrenergic Agonist
zh: α-2肾上腺素能激动剂
ja: α2アドレナリン受容体作動薬
controlledSubstance: false
schedule:
US: Not scheduled
CN: Not approved for ADHD
EU: Not scheduled (not ADHD indication)
JP: Not approved for ADHD
UK: Not scheduled
activeIngredient:
en: clonidine hydrochloride
zh: 盐酸可乐定
ja: クロニジン塩酸塩
mechanismOfAction:
en: Alpha-2 adrenergic receptor agonist. Stimulates presynaptic alpha-2 receptors in the brain, reducing sympathetic outflow and norepinephrine release. In ADHD, thought to improve prefrontal cortex function, reduce hyperactivity, and improve impulse control.
zh: α-2肾上腺素能受体激动剂。刺激脑内突触前α-2受体,减少交感神经传出和去甲肾上腺素释放。在ADHD中,被认为可改善前额叶皮层功能,减少多动,改善冲动控制。
ja: α2アドレナリン受容体作動薬。脳内のシナプス前α2受容体を刺激し、交感神経出力とノルエピネフリン放出を減少させます。ADHDでは、前頭前皮質機能を改善し、多動性を軽減し、衝動制御を改善すると考えられています。
neurotransmittersAffected:
- norepinephrine
forms:
- type: tablet
typeLabel:
en: Tablet
zh: 片剂
ja: 錠剤
releaseType: extended
releaseTypeLabel:
en: Extended Release
zh: 缓释
ja: 徐放性
brandName: Kapvay
strengths:
- 0.1mg
- 0.2mg
durationHours: 12
notes:
en: FDA-approved for ADHD; twice daily dosing
zh: FDA批准用于ADHD;每日两次给药
ja: ADHDにFDA承認;1日2回投与
- type: tablet
typeLabel:
en: Tablet
zh: 片剂
ja: 錠剤
releaseType: immediate
releaseTypeLabel:
en: Immediate Release
zh: 速释
ja: 即放性
brandName: Catapres
strengths:
- 0.1mg
- 0.2mg
- 0.3mg
durationHours: 6-8
notes:
en: Approved for hypertension; used off-label for ADHD
zh: 批准用于高血压;用于ADHD为超说明书使用
ja: 高血圧に承認;ADHDには適応外使用
- type: patch
typeLabel:
en: Transdermal Patch
zh: 透皮贴剂
ja: 経皮パッチ
releaseType: extended
releaseTypeLabel:
en: Extended Release
zh: 缓释
ja: 徐放性
brandName: Catapres-TTS
strengths:
- 0.1mg/day
- 0.2mg/day
- 0.3mg/day
durationHours: 168
notes:
en: Transdermal patch; change weekly; off-label for ADHD
zh: 透皮贴剂;每周更换;用于ADHD为超说明书使用
ja: 経皮パッチ;毎週交換;ADHDには適応外使用
onsetMinutes:
peakEffectHours: 2-4
durationHours: 6-12
sideEffects:
common:
- name:
en: somnolence/drowsiness
zh: 嗜睡/困倦
ja: 傾眠/眠気
frequency: 30-40%
- name:
en: fatigue
zh: 疲劳
ja: 疲労
frequency: 20-30%
- name:
en: headache
zh: 头痛
ja: 頭痛
frequency: 15-20%
- name:
en: dry mouth
zh: 口干
ja: 口渇
frequency: 10-20%
- name:
en: dizziness
zh: 头晕
ja: めまい
frequency: 10-15%
- name:
en: irritability
zh: 易怒
ja: 易刺激性
frequency: 10%
- name:
en: upper respiratory infection
zh: 上呼吸道感染
ja: 上気道感染
frequency: 10%
uncommon:
- name:
en: hypotension
zh: 低血压
ja: 低血圧
frequency: 5-10%
- name:
en: bradycardia
zh: 心动过缓
ja: 徐脈
frequency: 5%
- name:
en: constipation
zh: 便秘
ja: 便秘
frequency: 5%
- name:
en: nausea
zh: 恶心
ja: 悪心
frequency: 5%
- name:
en: skin reactions (patch)
zh: 皮肤反应(贴剂)
ja: 皮膚反応(パッチ)
frequency: 5-15%
serious:
- name:
en: hypotension
zh: 低血压
ja: 低血圧
notes:
en: Significant drops in blood pressure possible
zh: 可能出现明显血压下降
ja: 血圧の著しい低下の可能性
- name:
en: bradycardia
zh: 心动过缓
ja: 徐脈
notes:
en: Can slow heart rate significantly
zh: 可能显著减慢心率
ja: 心拍数を著しく低下させる可能性
- name:
en: rebound hypertension
zh: 反跳性高血压
ja: リバウンド高血圧
notes:
en: Severe if stopped abruptly; MUST taper
zh: 突然停药时严重;必须逐渐减量
ja: 急に中止すると重度;必ず漸減すること
- name:
en: sedation
zh: 镇静
ja: 鎮静
notes:
en: Can be profound, especially early in treatment
zh: 可能很严重,尤其是治疗初期
ja: 特に治療初期は重度になる可能性
- name:
en: AV block
zh: 房室传导阻滞
ja: 房室ブロック
notes:
en: Rare cardiac conduction abnormalities
zh: 罕见的心脏传导异常
ja: まれな心臓伝導異常
contraindications:
en:
- Hypersensitivity to clonidine
- Severe bradyarrhythmia
- "Patch: skin irritation at application site"
zh:
- 对可乐定过敏
- 严重缓慢性心律失常
- 贴剂:贴敷部位皮肤刺激
ja:
- クロニジンに対する過敏症
- 重度の徐脈性不整脈
- パッチ:貼付部位の皮膚刺激
drugInteractions:
- drug:
en: Beta-blockers
zh: β受体阻滞剂
ja: β遮断薬
severity: major
effect:
en: Enhanced bradycardia, rebound hypertension risk if clonidine stopped
zh: 心动过缓增强,停用可乐定时有反跳性高血压风险
ja: 徐脈の増強、クロニジン中止時のリバウンド高血圧リスク
- drug:
en: Tricyclic antidepressants
zh: 三环类抗抑郁药
ja: 三環系抗うつ薬
severity: moderate
effect:
en: May reduce clonidine effectiveness
zh: 可能降低可乐定疗效
ja: クロニジンの効果を低下させる可能性
- drug:
en: CNS depressants
zh: 中枢神经抑制剂
ja: 中枢神経抑制剤
severity: moderate
effect:
en: Enhanced sedation
zh: 镇静作用增强
ja: 鎮静作用の増強
- drug:
en: Antihypertensives
zh: 降压药
ja: 降圧薬
severity: moderate
effect:
en: Additive hypotensive effect
zh: 降压作用叠加
ja: 降圧作用の相加
- drug:
en: Digoxin
zh: 地高辛
ja: ジゴキシン
severity: moderate
effect:
en: Enhanced AV block risk
zh: 房室传导阻滞风险增加
ja: 房室ブロックリスクの増加
blackBoxWarnings:
en: []
zh: []
ja: []
pregnancyCategory: C
foodInteractions:
en: Can be taken with or without food
zh: 可随餐或空腹服用
ja: 食事の有無にかかわらず服用可能
typicalDosing:
children:
startingDose: 0.1mg at bedtime
maxDose: 0.4mg/day (divided twice daily)
notes:
en: Increase by 0.1mg weekly; Kapvay is twice daily (morning and bedtime)
zh: 每周增加0.1mg;Kapvay为每日两次(早晨和睡前)
ja: 毎週0.1mgずつ増量;Kapvayは1日2回(朝と就寝時)
adults:
startingDose: 0.1mg twice daily
maxDose: 0.4mg/day
notes:
en: Off-label for adult ADHD
zh: 用于成人ADHD为超说明书使用
ja: 成人ADHDには適応外使用
costEstimate:
US:
brand: $200-300/month (Kapvay)
generic: $20-50/month
CN:
brand: Not available for ADHD
generic: Not available for ADHD
storageRequirements:
en: Room temperature (25°C), protect from light
zh: 室温保存(25°C),避光
ja: 室温(25°C)で保存、光を避ける
approvals:
- region: US
agency: FDA
year: 2010
approvedAges:
en: 6-17 years
zh: 6-17岁
ja: 6〜17歳
indications:
en:
- ADHD
zh:
- 注意缺陷多动障碍
ja:
- ADHD
available: true
notes:
en: Kapvay (ER) approved for ADHD; can be used alone or with stimulants
zh: Kapvay(缓释)批准用于ADHD;可单独使用或与兴奋剂联用
ja: Kapvay(徐放)がADHDに承認;単独または刺激薬との併用が可能
- region: CN
agency: NMPA
year:
approvedAges:
en: ""
zh: ""
ja: ""
indications:
en: []
zh: []
ja: []
available: false
notes:
en: Not approved for ADHD
zh: 未批准用于ADHD
ja: ADHDには未承認
- region: EU
agency: EMA
year:
approvedAges:
en: ""
zh: ""
ja: ""
indications:
en: []
zh: []
ja: []
available: false
notes:
en: Not specifically approved for ADHD; used off-label
zh: 未专门批准用于ADHD;为超说明书使用
ja: ADHDに特定の承認なし;適応外使用
- region: JP
agency: PMDA
year:
approvedAges:
en: ""
zh: ""
ja: ""
indications:
en: []
zh: []
ja: []
available: false
notes:
en: Not approved for ADHD
zh: 未批准用于ADHD
ja: ADHDには未承認
- region: UK
agency: MHRA
year:
approvedAges:
en: ""
zh: ""
ja: ""
indications:
en: []
zh: []
ja: []
available: false
notes:
en: Not specifically approved for ADHD; sometimes used off-label
zh: 未专门批准用于ADHD;有时超说明书使用
ja: ADHDに特定の承認なし;適応外使用されることがある
specialConsiderations:
cardiacRisk:
en: Significant cardiovascular effects; monitor BP and HR closely
zh: 心血管影响显著;需密切监测血压和心率
ja: 心血管への影響が大きい;血圧と心拍数を注意深くモニタリング
abuseRisk:
en: No abuse potential; not a controlled substance
zh: 无滥用风险;非管制药物
ja: 乱用の可能性なし;規制物質ではない
withdrawalNotes:
en: "CRITICAL: Must taper slowly. Abrupt discontinuation can cause severe rebound hypertension, agitation, and other serious effects"
zh: 重要:必须缓慢减量。突然停药可导致严重的反跳性高血压、激动和其他严重后果
ja: 重要:必ずゆっくりと漸減すること。急な中止は重度のリバウンド高血圧、興奮、その他の重篤な影響を引き起こす可能性
monitoringRequired:
en: Blood pressure and heart rate at each visit; ECG if cardiac concerns
zh: 每次就诊时监测血压和心率;如有心脏问题需做心电图
ja: 毎回の診察時に血圧と心拍数;心臓に懸念がある場合はECG
travelRules:
generalAdvice:
en: "Clonidine is NOT a controlled substance, making travel straightforward. Note: Only approved for ADHD in the US (Kapvay). Other regions use it off-label for ADHD."
zh: 可乐定不是管制药物,旅行较为简单。注意:仅在美国获批用于ADHD(Kapvay)。其他地区用于ADHD为超说明书使用。
ja: クロニジンは規制物質ではないため、旅行は簡単です。注意:ADHDへの承認は米国(Kapvay)のみ。他の地域ではADHDへの適応外使用です。
requiredDocumentation:
- type: prescription
typeLabel:
en: Valid prescription
zh: 有效处方
ja: 有効な処方箋
notes:
en: Recommended for longer trips
zh: 长途旅行建议携带
ja: 長期旅行の場合は推奨
maxPersonalSupply:
default: 90 days
crossBorderRules:
- fromRegion: US
toRegion: JP
status: allowed
statusLabel:
en: Allowed
zh: 允许
ja: 許可
requirements:
en:
- Carry prescription copy
- Keep in original packaging
zh:
- 携带处方副本
- 保持原包装
ja:
- 処方箋のコピーを携帯
- 元のパッケージを維持
maxSupply: 90 days
notes:
en: Clonidine is available in Japan (for hypertension). Not a controlled substance.
zh: 可乐定在日本可用(用于高血压)。不是管制药物。
ja: クロニジンは日本で入手可能(高血圧用)。規制物質ではありません。
- fromRegion: US
toRegion: CN
status: allowed
statusLabel:
en: Allowed
zh: 允许
ja: 許可
requirements:
en:
- Carry prescription copy
- Keep in original packaging
zh:
- 携带处方副本
- 保持原包装
ja:
- 処方箋のコピーを携帯
- 元のパッケージを維持
maxSupply: 90 days
notes:
en: Clonidine is available in China (for hypertension). Personal use quantities allowed.
zh: 可乐定在中国可用(用于高血压)。允许个人使用量。
ja: クロニジンは中国で入手可能(高血圧用)。個人使用量は許可されています。
- fromRegion: US
toRegion: EU
status: allowed
statusLabel:
en: Allowed
zh: 允许
ja: 許可
requirements:
en:
- Carry prescription copy
zh:
- 携带处方副本
ja:
- 処方箋のコピーを携帯
maxSupply: 90 days
notes:
en: Clonidine is available in EU. No special import requirements.
zh: 可乐定在欧盟可用。无特殊进口要求。
ja: クロニジンはEUで入手可能です。特別な輸入要件はありません。
rxnormData:
ingredientRxcui: "2599"
ingredientName: clonidine
rxcuiMappings:
- rxcui: "2599"
name: clonidine
tty: IN
description: Base ingredient
- rxcui: "1013931"
name: Kapvay
tty: BN
description: Brand name
- rxcui: "1050312"
name: Nexiclon
tty: BN
description: Brand name
- rxcui: "202941"
name: Catapres
tty: BN
description: Brand name
- rxcui: "216099"
name: Clorpres
tty: BN
description: Brand name
- rxcui: "216778"
name: Duraclon
tty: BN
description: Brand name
- rxcui: "2690729"
name: Onyda
tty: BN
description: Brand name
- rxcui: "2725555"
name: Javadin
tty: BN
description: Brand name
- rxcui: "142432"
name: clonidine hydrochloride
tty: PIN
description: Precise ingredient (includes salt form)
- rxcui: "1013934"
name: 12 HR clonidine hydrochloride 0.1 MG Extended Release Oral Tablet [Kapvay]
tty: SBD
description: Branded drug (brand + strength + form)
- rxcui: "1050338"
name: 24 HR clonidine 0.17 MG Extended Release Oral Tablet [Nexiclon]
tty: SBD
description: Branded drug (brand + strength + form)
- rxcui: "2690735"
name: 24 HR clonidine hydrochloride 0.1 MG/ML Extended Release Suspension [Onyda]
tty: SBD
description: Branded drug (brand + strength + form)
- rxcui: "2725561"
name: clonidine hydrochloride 0.02 MG/ML Oral Solution [Javadin]
tty: SBD
description: Branded drug (brand + strength + form)
- rxcui: "884196"
name: chlorthalidone 15 MG / clonidine hydrochloride 0.1 MG Oral Tablet [Clorpres]
tty: SBD
description: Branded drug (brand + strength + form)
- rxcui: "884202"
name: chlorthalidone 15 MG / clonidine hydrochloride 0.2 MG Oral Tablet [Clorpres]
tty: SBD
description: Branded drug (brand + strength + form)
- rxcui: "884207"
name: chlorthalidone 15 MG / clonidine hydrochloride 0.3 MG Oral Tablet [Clorpres]
tty: SBD
description: Branded drug (brand + strength + form)
- rxcui: "884223"
name: 10 ML clonidine hydrochloride 0.1 MG/ML Injection [Duraclon]
tty: SBD
description: Branded drug (brand + strength + form)
- rxcui: "998673"
name: 168 HR clonidine 0.00417 MG/HR Transdermal System [Catapres]
tty: SBD
description: Branded drug (brand + strength + form)
- rxcui: "998677"
name: 168 HR clonidine 0.00833 MG/HR Transdermal System [Catapres]
tty: SBD
description: Branded drug (brand + strength + form)
- rxcui: "998681"
name: 168 HR clonidine 0.0125 MG/HR Transdermal System [Catapres]
tty: SBD
description: Branded drug (brand + strength + form)
- rxcui: "1013933"
name: clonidine Extended Release Oral Tablet [Kapvay]
tty: SBDF
description: Branded ingredient + dose form
- rxcui: "1050333"
name: clonidine Extended Release Oral Tablet [Nexiclon]
tty: SBDF
description: Branded ingredient + dose form
- rxcui: "1732372"
name: clonidine Injection [Duraclon]
tty: SBDF
description: Branded ingredient + dose form
- rxcui: "2268636"
name: clonidine Transdermal System [Catapres]
tty: SBDF
description: Branded ingredient + dose form
- rxcui: "2690733"
name: clonidine Extended Release Suspension [Onyda]
tty: SBDF
description: Branded ingredient + dose form
- rxcui: "2725559"
name: clonidine Oral Solution [Javadin]
tty: SBDF
description: Branded ingredient + dose form
- rxcui: "884195"
name: chlorthalidone / clonidine Oral Tablet [Clorpres]
tty: SBDF
description: Branded ingredient + dose form
- rxcui: "1013930"
name: 12 HR clonidine hydrochloride 0.1 MG Extended Release Oral Tablet
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "2690727"
name: 24 HR clonidine hydrochloride 0.1 MG/ML Extended Release Suspension
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "2725554"
name: clonidine hydrochloride 0.02 MG/ML Oral Solution
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "884173"
name: clonidine hydrochloride 0.1 MG Oral Tablet
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "884185"
name: clonidine hydrochloride 0.2 MG Oral Tablet
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "884189"
name: clonidine hydrochloride 0.3 MG Oral Tablet
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "884192"
name: chlorthalidone 15 MG / clonidine hydrochloride 0.1 MG Oral Tablet
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "884198"
name: chlorthalidone 15 MG / clonidine hydrochloride 0.2 MG Oral Tablet
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "884203"
name: chlorthalidone 15 MG / clonidine hydrochloride 0.3 MG Oral Tablet
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "884221"
name: 10 ML clonidine hydrochloride 0.1 MG/ML Injection
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "884225"
name: 10 ML clonidine hydrochloride 0.5 MG/ML Injection
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "885880"
name: 24 HR clonidine 0.17 MG Extended Release Oral Tablet
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "892791"
name: clonidine hydrochloride 0.025 MG Oral Tablet
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "892793"
name: clonidine hydrochloride 0.15 MG/ML Injectable Solution
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "892795"
name: clonidine hydrochloride 0.25 MG Extended Release Oral Capsule
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "998671"
name: 168 HR clonidine 0.00417 MG/HR Transdermal System
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "998675"
name: 168 HR clonidine 0.00833 MG/HR Transdermal System
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "998679"
name: 168 HR clonidine 0.0125 MG/HR Transdermal System
tty: SCD
description: Clinical drug (ingredient + strength + form)
- rxcui: "1732370"
name: clonidine Injection
tty: SCDF
description: Ingredient + dose form
- rxcui: "1806253"
name: clonidine Transdermal System
tty: SCDF
description: Ingredient + dose form
- rxcui: "2725552"
name: clonidine Oral Solution
tty: SCDF
description: Ingredient + dose form
- rxcui: "371580"
name: chlorthalidone / clonidine Oral Tablet
tty: SCDF
description: Ingredient + dose form
- rxcui: "371581"
name: clonidine Extended Release Oral Capsule
tty: SCDF
description: Ingredient + dose form
- rxcui: "371582"
name: clonidine Injectable Solution
tty: SCDF
description: Ingredient + dose form
- rxcui: "371583"
name: clonidine Oral Tablet
tty: SCDF
description: Ingredient + dose form
- rxcui: "885790"
name: clonidine Extended Release Suspension
tty: SCDF
description: Ingredient + dose form
- rxcui: "885794"
name: clonidine Extended Release Oral Tablet
tty: SCDF
description: Ingredient + dose form
brandMappings:
- brandName: Kapvay
rxcui: "1013931"
region: US
- brandName: Nexiclon
rxcui: "1050312"
region: US
- brandName: Catapres
rxcui: "202941"
region: US
- brandName: Clorpres
rxcui: "216099"
region: US
- brandName: Duraclon
rxcui: "216778"
region: US
- brandName: Onyda
rxcui: "2690729"
region: US
- brandName: Javadin
rxcui: "2725555"
region: US
synonyms:
- name: clonidine hydrochloride
type: chemical
source: RxNorm
- name: Kapvay
type: brand
source: RxNorm
- name: Nexiclon
type: brand
source: RxNorm
- name: Catapres
type: brand
source: RxNorm
- name: Clorpres
type: brand
source: RxNorm
- name: Duraclon
type: brand
source: RxNorm
- name: Onyda
type: brand
source: RxNorm
- name: Javadin
type: brand
source: RxNorm
- name: clonidine
type: generic
source: RxNorm
relatedDrugs:
- rxcui: "1013930"
name: 12 HR clonidine hydrochloride 0.1 MG Extended Release Oral Tablet
tty: SCD
relationship: clinical_drug
- rxcui: "2690727"
name: 24 HR clonidine hydrochloride 0.1 MG/ML Extended Release Suspension
tty: SCD
relationship: clinical_drug
- rxcui: "2725554"
name: clonidine hydrochloride 0.02 MG/ML Oral Solution
tty: SCD
relationship: clinical_drug
- rxcui: "884173"
name: clonidine hydrochloride 0.1 MG Oral Tablet
tty: SCD
relationship: clinical_drug
- rxcui: "884185"
name: clonidine hydrochloride 0.2 MG Oral Tablet
tty: SCD
relationship: clinical_drug
- rxcui: "884189"
name: clonidine hydrochloride 0.3 MG Oral Tablet
tty: SCD
relationship: clinical_drug
- rxcui: "884192"
name: chlorthalidone 15 MG / clonidine hydrochloride 0.1 MG Oral Tablet
tty: SCD
relationship: clinical_drug
- rxcui: "884198"
name: chlorthalidone 15 MG / clonidine hydrochloride 0.2 MG Oral Tablet
tty: SCD
relationship: clinical_drug
- rxcui: "884203"
name: chlorthalidone 15 MG / clonidine hydrochloride 0.3 MG Oral Tablet
tty: SCD
relationship: clinical_drug
- rxcui: "884221"
name: 10 ML clonidine hydrochloride 0.1 MG/ML Injection
tty: SCD
relationship: clinical_drug
- rxcui: "884225"
name: 10 ML clonidine hydrochloride 0.5 MG/ML Injection
tty: SCD
relationship: clinical_drug
- rxcui: "885880"
name: 24 HR clonidine 0.17 MG Extended Release Oral Tablet
tty: SCD
relationship: clinical_drug
- rxcui: "892791"
name: clonidine hydrochloride 0.025 MG Oral Tablet
tty: SCD
relationship: clinical_drug
- rxcui: "892793"
name: clonidine hydrochloride 0.15 MG/ML Injectable Solution
tty: SCD
relationship: clinical_drug
- rxcui: "892795"
name: clonidine hydrochloride 0.25 MG Extended Release Oral Capsule
tty: SCD
relationship: clinical_drug
- rxcui: "998671"
name: 168 HR clonidine 0.00417 MG/HR Transdermal System
tty: SCD
relationship: clinical_drug
- rxcui: "998675"
name: 168 HR clonidine 0.00833 MG/HR Transdermal System
tty: SCD
relationship: clinical_drug
- rxcui: "998679"
name: 168 HR clonidine 0.0125 MG/HR Transdermal System
tty: SCD
relationship: clinical_drug
- rxcui: "1013934"
name: 12 HR clonidine hydrochloride 0.1 MG Extended Release Oral Tablet [Kapvay]
tty: SBD
relationship: branded_drug
- rxcui: "1050338"
name: 24 HR clonidine 0.17 MG Extended Release Oral Tablet [Nexiclon]
tty: SBD
relationship: branded_drug
- rxcui: "2690735"
name: 24 HR clonidine hydrochloride 0.1 MG/ML Extended Release Suspension [Onyda]
tty: SBD
relationship: branded_drug
- rxcui: "2725561"
name: clonidine hydrochloride 0.02 MG/ML Oral Solution [Javadin]
tty: SBD
relationship: branded_drug
- rxcui: "884196"
name: chlorthalidone 15 MG / clonidine hydrochloride 0.1 MG Oral Tablet [Clorpres]
tty: SBD
relationship: branded_drug
- rxcui: "884202"
name: chlorthalidone 15 MG / clonidine hydrochloride 0.2 MG Oral Tablet [Clorpres]
tty: SBD
relationship: branded_drug
- rxcui: "884207"
name: chlorthalidone 15 MG / clonidine hydrochloride 0.3 MG Oral Tablet [Clorpres]
tty: SBD
relationship: branded_drug
- rxcui: "884223"
name: 10 ML clonidine hydrochloride 0.1 MG/ML Injection [Duraclon]
tty: SBD
relationship: branded_drug
- rxcui: "998673"
name: 168 HR clonidine 0.00417 MG/HR Transdermal System [Catapres]
tty: SBD
relationship: branded_drug
- rxcui: "998677"
name: 168 HR clonidine 0.00833 MG/HR Transdermal System [Catapres]
tty: SBD
relationship: branded_drug
- rxcui: "998681"
name: 168 HR clonidine 0.0125 MG/HR Transdermal System [Catapres]
tty: SBD
relationship: branded_drug
- rxcui: "1732370"
name: clonidine Injection
tty: SCDF
relationship: drug_form
lastUpdated: 2025-12-04
instructions:
indicationsAndUsage:
en: |
Clonidine extended-release (Kapvay) is an alpha2-adrenergic agonist indicated for the treatment of:
- Attention Deficit Hyperactivity Disorder (ADHD) in patients 6-17 years of age as monotherapy or adjunctive therapy to stimulants
Note: Immediate-release clonidine (Catapres) is FDA-approved for hypertension, not ADHD. ADHD use of IR formulations is off-label. Clonidine patches are also for hypertension only.
dosageAndAdministration:
en: |
ADHD (KAPVAY EXTENDED-RELEASE):
- Starting dose: 0.1 mg at bedtime
- Week 2: 0.1 mg twice daily (morning and bedtime)
- Week 3: 0.1 mg in morning, 0.2 mg at bedtime
- Week 4+: 0.2 mg twice daily
- Maximum dose: 0.4 mg/day (0.2 mg twice daily)
ADJUNCTIVE THERAPY WITH STIMULANTS:
- Same dosing as monotherapy
- Total daily dose can be given as twice daily
General Instructions:
- Take twice daily (morning and bedtime)
- Equal or higher split dosage should be given at bedtime
- May be taken with or without food
- Swallow tablets whole; do NOT crush, chew, or break (extended-release)
DISCONTINUATION:
- CRITICAL: Taper gradually over 3-7 days
- Reduce dose by no more than 0.1 mg every 3-7 days
- Abrupt discontinuation can cause severe rebound hypertension
OFF-LABEL IR DOSING (CATAPRES):
- Typically 0.05-0.1 mg 2-4 times daily
- Often used at bedtime for sleep issues
- Must also be tapered when discontinuing
dosageForms:
en: |
Extended-Release Tablets (Kapvay): 0.1 mg, 0.2 mg (FDA-approved for ADHD)
Immediate-Release Tablets (Catapres): 0.1 mg, 0.2 mg, 0.3 mg (off-label for ADHD)
Transdermal Patch (Catapres-TTS): 0.1 mg/day, 0.2 mg/day, 0.3 mg/day (hypertension only)
contraindications:
en: |
Clonidine is contraindicated in patients with:
- Known hypersensitivity to clonidine or any components of the formulation
CAUTIONS (Use with Extreme Care):
- Patients with severe cardiovascular disease
- History of syncope
- Conditions predisposing to syncope (hypotension, dehydration)
- Patients on other antihypertensives or drugs affecting blood pressure
warningsAndPrecautions:
en: |
HYPOTENSION AND BRADYCARDIA:
- Can cause dose-dependent decreases in blood pressure and heart rate
- Syncope has been reported
- Measure blood pressure and heart rate before initiation and periodically during treatment
- Titrate slowly and monitor during dose adjustments
SEDATION AND SOMNOLENCE:
- Common adverse reaction
- Patients should avoid activities requiring mental alertness until effects are known
- May be more pronounced when combined with CNS depressants
REBOUND HYPERTENSION (CRITICAL):
- Sudden discontinuation can cause nervous system hyperactivity resulting in:
• Rapid rise in blood pressure
• Headache
• Agitation
• Tremor
• Confusion
- Always taper dose gradually
- If switching from patch to oral: overlap for 1-2 days
CARDIAC CONDUCTION ABNORMALITIES:
- Use caution in patients with conduction disturbances
- May worsen sinus node dysfunction and AV block
- Caution with other drugs affecting heart rate/rhythm
ALLERGIC REACTIONS:
- Patches may cause localized skin reactions and rarely systemic allergic reactions
adverseReactions:
en: |
Most Common Adverse Reactions (≥5%):
- Somnolence (31-38%)
- Fatigue (16%)
- Irritability (9%)
- Insomnia (less common with bedtime dosing)
- Nightmares
- Emotional disorder
- Constipation
- Dry mouth
- Upper abdominal pain
Other Notable Adverse Reactions:
- Hypotension
- Bradycardia
- Dizziness
- Headache
- Nausea
- Decreased appetite
Patch-Specific (Transdermal):
- Localized skin reactions (erythema, pruritus)
- Contact dermatitis
drugInteractions:
en: |
USE WITH CAUTION:
- Antihypertensives: Additive hypotensive effects
- CNS Depressants (sedatives, hypnotics, alcohol): Enhanced CNS depression
- Tricyclic Antidepressants: May reduce clonidine's antihypertensive effect
- Beta-blockers: Additive bradycardia; if stopping both, taper beta-blocker first, then clonidine
- Digitalis: Additive effects on AV conduction and heart rate
- Calcium channel blockers: Additive bradycardia and hypotension
- Drugs affecting renal function: May affect clonidine elimination
IMPORTANT:
- Abrupt withdrawal of beta-blockers while on clonidine can cause severe hypertension
- Always discontinue beta-blockers several days before clonidine taper
useInSpecificPopulations:
en: |
PREGNANCY:
- Category C. Use only if potential benefit justifies risk to fetus.
- Crosses placenta
LACTATION:
- Clonidine is excreted in human milk
- Consider benefits of breastfeeding vs. potential risks
PEDIATRIC USE:
- Kapvay: Safety and efficacy established for patients 6-17 years
- Not recommended for children under 6 years
GERIATRIC USE:
- Clinical studies did not include sufficient patients 65 and older
- May be more sensitive to hypotensive effects
RENAL IMPAIRMENT:
- Clonidine is primarily renally excreted
- Consider dose reduction; monitor closely
- Adjust dose according to renal function
overdosage:
en: |
SIGNS AND SYMPTOMS:
- Hypotension
- Bradycardia
- Lethargy/drowsiness
- Diminished or absent reflexes
- Weakness, irritability
- Miosis (constricted pupils)
- Hypothermia
- Respiratory depression (large doses)
- Reversible cardiac conduction abnormalities/arrhythmias
- Apnea, seizures (rarely, in children)
TREATMENT:
- Supportive treatment as primary therapy
- Monitor cardiac and respiratory function
- Atropine for symptomatic bradycardia
- Intravenous fluids and/or vasopressors for hypotension
- Tolazoline has been used to treat clonidine overdose
- Dialysis is not effective
clinicalPharmacology:
en: |
MECHANISM OF ACTION:
Clonidine is a centrally acting alpha2-adrenergic agonist. It works by:
- Stimulating alpha2-adrenergic receptors in the brain stem
- Reducing sympathetic outflow from the CNS
- Decreasing peripheral resistance, heart rate, and blood pressure
- In ADHD: thought to improve prefrontal cortex function and reduce hyperactivity/impulsivity
Unlike guanfacine, clonidine is less selective for alpha2A receptors, which may explain its more pronounced sedative effects.
PHARMACOKINETICS:
- Absorption: Well absorbed; bioavailability ~70%
- Peak concentration: 7-8 hours (extended-release); 1-3 hours (immediate-release)
- Distribution: Widely distributed; crosses blood-brain barrier
- Metabolism: Hepatic (minor); 50% excreted unchanged
- Half-life: 12-16 hours (allows twice-daily dosing for ER)
- Excretion: 72% renal (50% unchanged); 22% fecal
howSupplied:
en: |
STORAGE AND HANDLING:
- Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)
- Protect from light
Not a Controlled Substance - No DEA Schedule
patientCounselingInfo:
en: |
IMPORTANT PATIENT INFORMATION:
1. DO NOT STOP SUDDENLY (CRITICAL): Stopping this medication abruptly can cause dangerous spikes in blood pressure. Always taper gradually as directed by your doctor.
2. DROWSINESS: This medication causes significant drowsiness, especially at first. Avoid driving or operating machinery until you know how it affects you.
3. DOSING: Take twice daily. Take the larger dose at bedtime. Swallow extended-release tablets whole.
4. LOW BLOOD PRESSURE: Rise slowly from sitting or lying positions to avoid dizziness.
5. AVOID ALCOHOL: Alcohol increases drowsiness and may worsen blood pressure effects.
6. MISSED DOSES: If you miss two or more doses, contact your doctor before restarting - you may need to restart at a lower dose.
7. SURGERY: Tell your surgeon you take this medication. It may interact with anesthesia.
8. HEAT EXPOSURE: If using the patch, be aware that heat can increase drug absorption.
9. NOT A STIMULANT: This is a non-stimulant medication. It may take several weeks to see full effect.
10. MONITORING: Blood pressure and heart rate will be checked regularly during treatment.
lastUpdated: 2025-12-04
sources:
- https://www.goodrx.com/conditions/adhd/non-stimulant-adhd-meds
- https://www.additudemag.com/adhd-medications-list-chart-stimulants-nonstimulants/
notes:
en: "Less selective than guanfacine; more sedating. Only FDA-approved for ADHD in US (Kapvay). Helpful for hyperactivity, impulsivity, and sleep issues. Often used as adjunct to stimulants. CRITICAL: Never stop abruptly due to rebound hypertension risk."
zh: 选择性低于胍法辛;镇静作用更强。在美国仅Kapvay获FDA批准用于ADHD。对多动、冲动和睡眠问题有帮助。常作为兴奋剂的辅助用药。重要:由于反跳性高血压风险,切勿突然停药。
ja: グアンファシンより選択性が低い;鎮静作用が強い。米国ではKapvayのみがADHDにFDA承認。多動性、衝動性、睡眠の問題に有用。刺激薬の補助としてよく使用される。重要:リバウンド高血圧リスクのため、急な中止は禁忌。
在 GitHub 上編輯以貢獻